Mifepristone Access Under Threat
FDA Launches Mifepristone Study; Advocates Warn of Post-Roe Access Threat
The FDA has launched a six-month safety study of mifepristone, the abortion pill, following reporting that the effort could set up the Trump administration to impose tighter limits on how the drug is prescribed, distributed, and accessed. Officials say the study will rely on existing drug-safety monitoring systems and is designed to withstand potential legal challenges, with some preliminary internal results expected in July and full findings unlikely before the November midterm elections. The FDA is also considering hiring a contractor to collect and analyze real-world data on mifepristone use, expanding evidence beyond earlier clinical records. The FDA maintains that mifepristone remains safe and effective when used as directed. The move comes after the U.S. Supreme Court restored a 2023 rule that preserved access through telemedicine and by mail, even as legal disputes continue. Abortion-rights advocates warn that renewed scrutiny could pose the biggest threat to mifepristone access in the post-Roe landscape.
Key Points
Multiple reports said the FDA study is backed by the White House (not just initiated by the agency), which could help explain how it might be used to support future policy moves on prescribing, distribution, and access.
Reuters added context on the medication’s role in abortion care: medical abortion typically involves a two-drug regimen (mifepristone followed by misoprostol), and accounts for about two-thirds of U.S. abortions, typically used within the first 10 weeks of pregnancy.
Reuters reported that it could not immediately verify the Wall Street Journal’s account of the FDA study, and that the FDA did not respond to Reuters’ request for comment outside regular office hours.
One report said the timing of the safety review has raised questions about whether it is being used strategically to influence the political debate over reproductive health policy.
Sentiment
Mostly NegativePublishers
10
Articles
33
Reach
43
